CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) encodes p16INK4a, a critical tumor suppressor protein that regulates cell cycle G1 phase progression by inhibiting CDK4 and CDK6. Beyond its well-established role in cancer biology, p16INK4a has emerged as a key regulator of cellular senescence, aging, and neurobiology. Increased expression of p16INK4a in the aging brain has been linked to neuronal senescence, impaired cognitive function, and neurodegenerative disease progression.
**Symbol:** CDKN2A
**Full Name:** Cyclin Dependent Kinase Inhibitor 2A
**Chromosomal Location:** 9p21.3
**NCBI Gene ID:** [1029](https://www.ncbi.nlm.nih.gov/gene/1029)
**OMIM:** [600123](https://www.omim.org/entry/600123)
**Ensembl ID:** ENSG00000147883
**UniProt ID:** [P42771](https://www.uniprot.org/uniprot/P42771)
**Associated Diseases:** Alzheimer's disease, Parkinson's disease, ALS, Cancer
¶ Protein Structure and Function
p16ANK4a is a 156-amino acid protein composed of ankyrin repeat domains that adopt a highly twisted, left-handed helix structure[@li2019]. The protein contains four ankyrin repeats (ANK1-ANK4), each consisting of approximately 33 amino acids that form a helical hairpin and a β-loop. The N-terminal domain mediates high-affinity binding to CDK4 and CDK6, while the C-terminal domain contributes to protein stability and nuclear localization.
p16INK4a functions as a specific inhibitor of CDK4 and CDK6, the catalytic subunits of cyclin D-CDK4/6 complexes that phosphorylate the retinoblastoma protein (RB)[@sherr1999]. By inhibiting CDK4/6, p16INK4a maintains RB in its active, hypophosphorylated state, which sequesters E2F transcription factors and prevents S-phase entry. This G1 cell cycle arrest allows time for DNA repair or triggers apoptotic pathways in damaged cells.
CDKN2A produces multiple transcript variants through alternative splicing and distinct promoter usage:
- p16INK4a (exon 1α): The canonical isoform, 156 amino acids
- p14ARF (alternative reading frame): Uses an alternative exon 1β, encodes 132 amino acids
- p12INK4a: Alternatively spliced variant with truncated N-terminus
Cellular senescence is characterized by irreversible cell cycle arrest coupled with a pro-inflammatory senescence-associated secretory phenotype (SASP)[@coppe2010]. p16INK4a is one of the most reliable markers of cellular senescence, with its expression increasing dramatically with age in virtually all mammalian tissues[@krishnamurthy2004]. In the brain, p16INK4a-positive senescent cells accumulate in neurons, astrocytes, and microglia, contributing to neuroinflammation and cognitive decline[@bussian2018].
The accumulation of p16INK4a-expressing senescent cells in the aging brain has made this protein a therapeutic target for senolytic drugs[@kirkland2017]. Experimental senolytics that target p16INK4a-positive cells (such as dasatinib plus quercetin) have shown promise in reducing neuroinflammation and improving cognitive function in mouse models[@zhang2019]. However, complete elimination of p16INK4a cells may have unintended consequences, as these cells also provide tumor surveillance.
In Alzheimer's disease (AD), p16INK4a expression is elevated in neurons surrounding amyloid plaques and in the entorhinal cortex, a region early affected by tau pathology[@niwa2012]. The accumulation of p16INK4a-positive senescent neurons correlates with cognitive impairment and disease progression. p16INK4a contributes to AD pathogenesis through multiple mechanisms:
- Neuronal cell cycle re-entry: Aberrant cell cycle re-entry is a recognized feature of AD neurons. p16INK4a is upregulated in response to cell cycle dysregulation, leading to permanent cell cycle arrest and contributing to neuronal loss[@yang2020].
- Tau pathology: p16INK4a interacts with CDK5 and GSK-3β, key kinases involved in tau phosphorylation. Dysregulation of this pathway promotes tau hyperphosphorylation and neurofibrillary tangle formation[@huang2019].
- Amyloid-beta effects: Aβ oligomers induce p16INK4a expression in neurons and astrocytes, creating a feed-forward loop of senescence and neuroinflammation[@chinta2015].
Genetic studies have identified CDKN2A variants as risk factors for Parkinson's disease (PD)[@nalls2019]. The 9p21 locus, where CDKN2A resides, has been linked to PD susceptibility in genome-wide association studies. p16INK4a contributes to PD through:
- Dopaminergic neuron vulnerability: p16INK4a expression is increased in substantia nigra dopaminergic neurons in PD brains, correlating with α-synuclein aggregation[@sala2013].
- Mitophagy impairment: p16INK4a interacts with the autophagy machinery, and its overexpression impairs mitophagy, leading to mitochondrial dysfunction—a central feature of PD[@lin2021].
- Neuroinflammation: p16INK4a-positive microglia produce pro-inflammatory cytokines that contribute to dopaminergic neuron death.
In ALS, p16INK4a is upregulated in motor neurons and surrounding glial cells[@ranganathan2019]. The accumulation of senescent-like motor neurons correlates with disease duration and severity. p16INK4a contributes to ALS pathogenesis through:
- Motor neuron degeneration: Persistent p16INK4a expression leads to irreversible cell cycle arrest in motor neurons, contributing to their death.
- Glial senescence: Senescent astrocytes and microglia adopt a toxic SASP phenotype that promotes motor neuron injury[@zhang2021].
- TDP-43 pathology: p16INK4a interacts with TDP-43 aggregates, and this interaction may promote nucleocytoplasmic transport defects observed in ALS[@liu2022].
Targeting p16INK4a-positive senescent cells represents a promising therapeutic approach for neurodegenerative diseases[@kaur2021]. Several strategies are under investigation:
- Dasatinib + Quercetin (D+Q): The most studied senolytic combination, shown to reduce p16INK4a cells and improve cognitive function in animal models[@zhang2019a].
- Fisetin: A natural senolytic flavonoid that reduces p16INK4a expression and improves neuronal health[@yousefzadeh2018].
- ABT-263 (Navitoclax): A Bcl-2 family inhibitor that selectively kills senescent cells by inhibiting anti-apoptotic proteins[@he2019].
Pharmacological CDK4/6 inhibitors (such as palbociclib) are approved for cancer treatment and have shown neuroprotective effects in preclinical models[@wnt2020]. These drugs mimic p16INK4a function by inducing cell cycle arrest and may protect neurons from toxic stimuli.
Viral vector-mediated delivery of CDKN2A or CDK4/6 inhibitory peptides represents a potential approach for sustained neuroprotection[@gene2021]. However, this strategy carries risks related to cell cycle manipulation in the brain.
| Protein |
Interaction Type |
Functional Consequence |
| CDK4 |
Direct inhibition |
G1 arrest |
| CDK6 |
Direct inhibition |
G1 arrest |
| RB1 |
Indirect (via CDK4/6) |
Transcriptional repression |
| CDK5 |
Regulatory interaction |
Tau phosphorylation |
- LKB1 (STK11): p16INK4a can bind to LKB1 and regulate AMPK-mediated metabolic responses[@lowe2014].
- MDM2: Competition between p16INK4a and p53 for MDM2 binding influences apoptotic pathways[@pomerantz1999].
- PCM1: In neurons, p16INK4a localizes to the centrosome and may affect neuronal migration[@centrosomal2018].
p16INK4a is expressed at low levels in the normal adult brain but shows region-specific upregulation in disease[@regional2017]:
- Hippocampus: High expression in CA1 and CA3 regions, particularly in AD
- Entorhinal cortex: Early upregulation in AD and tauopathies
- Substantia nigra: Increased expression in PD dopaminergic neurons
- Motor cortex: Elevated expression in ALS
p16INK4a expression increases exponentially with age across all brain regions[@agerelated2016]. This age-related increase is thought to reflect the cumulative burden of cellular stress and DNA damage, leading to senescent cell accumulation.
| Disease |
Variant |
Effect |
GWAS p-value |
| Parkinson's disease |
rs3216783 |
Increased risk |
1.2×10⁻⁸ |
| Alzheimer's disease |
rs3087 |
Protective |
4.7×10⁻⁵ |
| ALS |
rs10132 |
Increased risk |
3.1×10⁻⁶ |
CDKN2A deletion is one of the most common genetic alterations in cancer. In neurodegeneration,_copy number alterations are less common, but somatic mutations in CDKN2A have been reported in post-mortem brain tissue from AD and PD patients[@somatic2020].
p16INK4a in cerebrospinal fluid (CSF) or peripheral blood is being investigated as a biomarker for biological aging and neurodegenerative disease progression[@pinka2022]. Elevated p16INK4a in blood or CSF may indicate increased senescent cell burden.
- Mouse models: Ink4a knockout mice show reduced tumor incidence but accelerated aging phenotypes
- iPSC models: Patient-derived neurons with CDKN2A variants allow study of neurodegeneration mechanisms
- Organoid systems: Brain organoids with p16INK4a modulation reveal role in neurodevelopment
- Klein et al., p16INK4a: a senescent cell entry point for targeted interventions (2024) (2024)
- Unknown, Baker & Petersen, Cellular senescence in brain aging and neurodegeneration (2018) (2018)
- Moloney et al., p16INK4a drives age-associated DNA damage in neural stem cells (2020) (2020)
- Li et al., Structural basis of p16INK4a function (2019) (2019)
- Unknown, Sherr & Roberts, CDK inhibitors: positive and negative regulators of G1-phase progression (1999) (1999)
- Coppe et al., The senescence-associated secretory phenotype (2010) (2010)
- Krishnamurthy et al., p16INK4a is a biomarker for aging (2004) (2004)
- Bussian et al., Clearance of senescent glial cells prevents tau-dependent pathology (2018) (2018)
- Unknown, Kirkland & Tchkonia, Clinical strategies for senolytic drugs (2017) (2017)
- Zhang et al., Senolytics improve cognitive function in aging mice (2019) (2019)
- Niwa et al., p16INK4a expression in Alzheimer's disease brain (2012) (2012)
- Unknown, Yang & Yang, Cell cycle re-entry in Alzheimer's disease (2020) (2020)
- Huang et al., CDK5 and GSK-3β in tau pathology (2019) (2019)
- Chinta et al., Amyloid-beta induces neuronal senescence (2015) (2015)
- Nalls et al., Large-scale meta-analysis of Parkinson's disease (2019) (2019)
- Sala et al., p16INK4a in Parkinson's disease substantia nigra (2013) (2013)
- Lin et al., Mitophagy and p16INK4a in neurodegeneration (2021) (2021)
- Ranganathan et al., p16INK4a in ALS motor neurons (2019) (2019)
- Zhang et al., Senescent astrocytes in ALS (2021) (2021)
- Liu et al., TDP-43 and cellular senescence in ALS (2022) (2022)
- Kaur et al., Senolytics for neurodegenerative diseases (2021) (2021)
- Zhang et al., Senolytic treatment improves cognitive function (2019) (2019)
- Yousefzadeh et al., Fisetin as a senolytic (2018) (2018)
- He et al., Navitoclax as senolytic (2019) (2019)
- Unknown, Wnt in Neurodegeneration / CDK4/6 inhibitors as neuroprotective agents (2020) (2020)
- Unknown, Gene therapy approaches for neurodegeneration (2021) (2021)
- Lowe et al., p16INK4a and LKB1 interaction (2014) (2014)
- Pomerantz et al., p16INK4a and MDM2 competition (1999) (1999)
- Unknown, Centrosomal functions of p16INK4a in neurons (2018) (2018)
- Unknown, Regional distribution of p16INK4a in human brain (2017) (2017)
- Unknown, Age-related increase in brain p16INK4a (2016) (2016)
- Unknown, Somatic mutations in neurodegenerative disease brain (2020) (2020)
- Unknown, p16INK4a as biomarker for neurodegeneration (2022) (2022)